Denali Therapeutics (DNLI) Cash & Equivalents (2017 - 2025)
Historic Cash & Equivalents for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $91.0 million.
- Denali Therapeutics' Cash & Equivalents rose 36.08% to $91.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.0 million, marking a year-over-year increase of 36.08%. This contributed to the annual value of $175.0 million for FY2024, which is 3764.89% up from last year.
- Latest data reveals that Denali Therapeutics reported Cash & Equivalents of $91.0 million as of Q3 2025, which was up 36.08% from $141.2 million recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Cash & Equivalents registered a high of $485.7 million during Q2 2021, and its lowest value of $56.9 million during Q1 2025.
- Its 5-year average for Cash & Equivalents is $177.4 million, with a median of $132.0 million in 2023.
- In the last 5 years, Denali Therapeutics' Cash & Equivalents soared by 25403.55% in 2021 and then tumbled by 7589.07% in 2022.
- Over the past 5 years, Denali Therapeutics' Cash & Equivalents (Quarter) stood at $293.5 million in 2021, then fell by 25.7% to $218.0 million in 2022, then crashed by 41.71% to $127.1 million in 2023, then skyrocketed by 37.65% to $175.0 million in 2024, then plummeted by 48.01% to $91.0 million in 2025.
- Its Cash & Equivalents was $91.0 million in Q3 2025, compared to $141.2 million in Q2 2025 and $56.9 million in Q1 2025.